FIELD: medicine.
SUBSTANCE: invention relates to medicine, specifically immunology, and can be used to treat inflammatory skin diseases. To this end, the pharmaceutical composition comprises a therapeutically effective amount of a PDE4 inhibitor and a vitamin D receptor agonist in an amount more than 100 times lower than the amount of the PDE4 inhibitor, as well as a pharmaceutically acceptable carrier or vehicle.
EFFECT: use of the present invention can the upregulation of the expression of the proinflammatory cytokine interleukin-22 by activated and differentiated human T cells without a concomitant effect on the proliferation of keratinocytes, said upregulation being induced by administration of a therapeutically effective amount of a phosphodiesterase 4 (PDE4) inhibitor.
9 cl, 7 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| IMPROVED IMMUNOLOGICAL COMPOSITION | 2012 |
|
RU2664730C2 |
| NEW BACTERIA AND THEIR EXTRACTS, AND USE THEREOF IN DERMATOLOGY | 2011 |
|
RU2612790C2 |
| THERAPEUTIC USE OF THE TLR AGONIST AND COMBINED THERAPY | 2011 |
|
RU2603467C2 |
| LIGAND GITR AND MOLECULES AND ANTIBODIES BOUND WITH LIGAND GITR, AND VERSIONS OF THEIR APPLICATION | 2004 |
|
RU2369636C2 |
| NEW LACTOBACILLUS PLANTARUM STRAIN, COMPOSITIONS CONTAINING IT, AND RELATED METHOD AND ITS USE | 2018 |
|
RU2790442C2 |
| NEW LACTIC ACID BACTERIA AND APPLICATION THEREOF | 2018 |
|
RU2752157C2 |
| APPLICATION OF NKG2D INHIBITORS FOR TREATING CARDIOVASCULAR AND METABOLIC DISEASES SUCH AS TYPE 2 DIABETES | 2010 |
|
RU2566264C2 |
| COMPOSITION CONTAINING Actinidia AND METHODS OF THEIR APPLICATION | 2006 |
|
RU2423139C2 |
| MODULATION OF EXPRESSION OF CYTOKINES TH1/TH2 BY RIBAVIRIN AND RIBAVIRIN ANALOGS IN ACTIVATED T-LYMPHOCYTES | 1997 |
|
RU2186569C2 |
| SYNTHETIC ANALOGS OF IL-10 | 1997 |
|
RU2194054C2 |
